RxDoctor Payments Data

Harish Chandna, MD

Cardiovascular Disease · Victoria, TXNPI 1013928688

Payments from drug & device makers

$337,893in general payments, 2019–2025

Across 705 payments — averaging $479.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$103K
  • AstraZeneca$94K
  • Kowa Research Institute, Inc.$36K
  • Esperion Therapeutics, Inc.$32K
  • Bayer$22K
  • Biotronik Inc.$14K
  • plus $37K from 26 others

What the payments were for

  • Consulting fees$11,2659%
  • Speaking & faculty fees$96,12077%
  • Travel & lodging$9,9468%
  • Food & beverage$7,0446%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$337,893 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$771,618
Medicare patients
920
Services billed
4,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban487$396,512
XareltoRivaroxaban149$133,058
FarxigaDapagliflozin Propanediol90$80,186
EntrestoSacubitril/Valsartan82$79,703
JardianceEmpagliflozin37$26,649
BrilintaTicagrelor24$11,833
Metoprolol Succinate443$4,453
ClopidogrelClopidogrel Bisulfate354$3,336
Flecainide Acetate97$2,906
Atorvastatin Calcium285$2,341
Losartan Potassium315$1,799
Ranolazine ErRanolazine20$1,782
Metoprolol Tartrate270$1,305
Isosorbide Mononitrate ErIsosorbide Mononitrate211$1,240
Nitroglycerin127$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,334$396,512487 claims
Johnson & JohnsonXarelto$102,611$133,058149 claims
AstraZenecaFarxiga, Brilinta$93,554$92,019114 claims
NovartisEntresto$535$79,70382 claims
Boehringer IngelheimJardiance$495$26,64937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →